ASCO GU 2018: Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

12:21 EST 8 Feb 2018 | ecancermedicalscience

Selected by the American Society of Clinical Oncology (ASCO) to first outing during its Genitourinary Cancers Symposium, Joaquin Mateo, principal investigator of VHIO's recently created Prostate Cancer Translational Research Group, has revealed findings...

Original Article: ASCO GU 2018: Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

NEXT ARTICLE

More From BioPortfolio on "ASCO GU 2018: Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer"